

# Luis Mas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3508081/publications.pdf>

Version: 2024-02-01

16  
papers

4,380  
citations

933447

10  
h-index

839539

18  
g-index

18  
all docs

18  
docs citations

18  
times ranked

5848  
citing authors

#	ARTICLE	IF	CITATIONS
1	Characteristics and outcomes of thymomas in Latin America: Results from over 10 years of experience (CLICaP-LATImus). Thoracic Cancer, 2021, 12, 1328-1335.	1.9	3
2	Epidemiology of thymic epithelial tumors: 22 years experience from a single institution. Thoracic Cancer, 2021, 12, 420-425.	1.9	2
3	Immunotherapy at any line of treatment improves survival in patients with advanced metastatic non-small cell lung cancer (NSCLC) compared with chemotherapy (Quijote-CLICaP). Thoracic Cancer, 2020, 11, 353-361.	1.9	36
4	Lung Cancer in the Young. Lung, 2020, 198, 195-200.	3.3	32
5	Antibiotics impair immune checkpoint inhibitor effectiveness in Hispanic patients with non-small cell lung cancer (<sc>AB-CLICaP</sc>). Thoracic Cancer, 2020, 11, 2552-2560.	1.9	12
6	Lung Cancer in Peru. Journal of Thoracic Oncology, 2020, 15, 891-898.	1.1	4
7	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet, The, 2019, 394, 1915-1928.	13.7	1,804
8	Characteristics and long-term outcomes of advanced pleural mesothelioma in Latin America (MeSO-CLICaP). Thoracic Cancer, 2019, 10, 508-518.	1.9	8
9	Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet, The, 2019, 393, 1819-1830.	13.7	2,347
10	ALK rearrangements: Biology, detection and opportunities of therapy in non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2019, 136, 48-55.	4.4	33
11	Level of tumor-infiltrating lymphocytes and density of infiltrating immune cells in different malignancies. Biomarkers in Medicine, 2019, 13, 1481-1491.	1.4	16
12	Anemia como factor pronóstico en pacientes con cáncer. Revista Peruana De Medicina De Experimental Y Salud Publica, 2018, 35, 250.	0.4	13
13	The implementation of the Plan Esperanza and response to the impACT Review. Lancet Oncology, The, 2017, 18, e595-e606.	10.7	29
14	An international epidemiological analysis of young patients with non-small cell lung cancer (AduJov-CLICaP). Lung Cancer, 2017, 113, 30-36.	2.0	27
15	Primary cutaneous T-cell lymphoma: experience from the Peruvian National Cancer Institute. Anais Brasileiros De Dermatologia, 2017, 92, 649-654.	1.1	6
16	Prevalence of EGFR mutations in the Peruvian population: Study in a large cohort of patients with NSCLC.. Journal of Clinical Oncology, 2017, 35, e13076-e13076.	1.6	2